## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																			
1. Name and Address of Reporting Person * Sigal Charles Elliott					2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner								
(Last) (First) (Middle) 32 BREARLY ROAD					3. Date of Earliest Transaction (Month/Day/Year) 05/19/2016							-	Officer	r (give title belo	ow)	Othe	er (spec	cify below	7)		
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person								
PRINCETON, NJ 08540 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
(Instr. 3) Date (Month/Day/Year)			Execut any	2A. Deemed Execution Date, if			Code					d 5. A Ber Rej	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form: Direct (D)		7. Nature of Indirect Beneficial Ownership			
								Cod	le	v	Amount	(A) or (D)	Price	÷				or Indirect (Instr. 4) (I) (Instr. 4)		·)	
Ordinary Shares with a nominal value of GBP0.001 per share (1)		05/19/2	2016				P			15,000	A	\$ 1.56 (3)	31	314,100 <sup>(4)</sup>			by Si I Fami			gal	
Ordinary Shares with a nominal value of GBP0.001 per share														52	52,938 (5)			D			
Reminder:	Report on a s	separate line	for each cl	Table II -	Deriv	ative Sec	curit	ties Ac	quir	Per cor the	rsons wh ntained i form dis	no res n this splay	form s a cu Benefi	are urren icially	not requ tly valid	ction of inf iired to res OMB cont	spond	unless	S	EC 147	74 (9-02)
	l <u> </u>	l	. I.		` ' '		s, w		ts, op		is, conver					0.71.0			4.0		44.37.
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transacti Date (Month/Day	y/Year) Ex	A. Deemed xecution Day Month/Day/	ate, if	Code		5. Numb of Deriv Secur Acqui (A) or Dispo of (D) (Instr. 4, and	ative ities ired rosed )	and Expiration Date (Month/Day/Year)  U		Amor Unde Secur (Instr	and and	of Derivative Security (Instr. 5) and  Derivative Security Security Benefi Owned Follow Repor Transa (Instr.		ative Ownersl Form of Derivati d Security ving Direct (l or Indire action(s) (I)		n of ivative urity: ect (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	V	(A)	(D)	Da Ex	ite ercisable	Expir Date	ation ,	Title	Amount or Number of Shares						

### **Reporting Owners**

D 41 0 N 4	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Sigal Charles Elliott 32 BREARLY ROAD PRINCETON, NJ 08540	X						

### **Signatures**

/s/ Charles Elliott Sigal	05/19/2016
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Dr. Sigal is a manager of Sigal Family Investments, LLC. Dr. Sigal may be deemed to have voting and investment power over the shares held by Sigal Family Investments, LLC. Dr. Sigal disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
- (2) The 15,000 Ordinary Shares are represented by 2,500 American Depositary Shares ("ADSs") which are held by Sigal Family Investments, LLC. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.
- (3) The price of \$1.56 per Ordinary Share was derived from the purchase price paid on May 19, 2016, of \$9.36 per ADS, divided by six.
- (4) The 314,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 60,000 Ordinary Shares represented by 10,000 ADSs.
- (5) The 52,938 Ordinary Shares are represented by 8,823 ADSs.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.